{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:15:42Z","timestamp":1793330142738,"version":"4.5.0"},"reference-count":91,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Long-term cure of childhood Burkitt lymphoma (BL) in sub-Saharan Africa after treatment with single-agent cyclophosphamide has been documented for more than half of a century. Contemporary cure rates for the highest-risk patients with BL in high-income countries exceed 90% using intensive multiagent chemotherapy. By contrast, the majority of African children with BL still die. Data spanning 5 decades in Africa have repeatedly shown that the children most likely to achieve cure with limited cyclophosphamide regimens are those with lower-stage disease isolated to the jaw. Attempts to intensify the cyclophosphamide monotherapy backbone with the addition of vincristine, low-dose methotrexate, prednisone, doxorubicin, and\/or low-dose cytarabine have not yielded significant improvement. High-dose methotrexate is a critical component in the treatment of childhood BL worldwide. Although initial efforts in Africa to incorporate high-dose methotrexate resulted in high treatment-related mortality, more recent collaborative experiences from North and West Africa, as well as Central America, demonstrate that it can be administered safely and effectively, despite limitations in supportive care resources. Recognizing the unacceptable disparity in curative outcomes for BL between the United States\/Europe and equatorial Africa, there is a critical need to safely adapt contemporary treatment regimens to optimize curative outcomes amid the resource limitations in regions where BL is endemic. Here, we critically review reports of BL treatment outcomes from low- and middle-income countries, in addition to data from high-income countries that predated modern intensified regimens, to identify potential strategies to improve the therapeutic approach for children suffering from BL in sub-Saharan Africa.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002178","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T12:03:58Z","timestamp":1598357038000},"page":"4007-4019","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa"],"prefix":"10.1182","volume":"4","author":[{"given":"Nmazuo W.","family":"Ozuah","sequence":"first","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX;"},{"name":"Texas Children\u2019s Cancer and Hematology Centers, Houston, TX;"},{"name":"Global HOPE Malawi, Lilongwe, Malawi; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lubega","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX;"},{"name":"Texas Children\u2019s Cancer and Hematology Centers, Houston, TX;"},{"name":"Global HOPE Uganda, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl E.","family":"Allen","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX;"},{"name":"Texas Children\u2019s Cancer and Hematology Centers, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-1046","authenticated-orcid":false,"given":"Nader Kim","family":"El-Mallawany","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX;"},{"name":"Texas Children\u2019s Cancer and Hematology Centers, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,8,25]]},"reference":[{"issue":"4","key":"2020082511345322100_B1","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S1470-2045(20)30022-X","article-title":"Sustainable care for children with cancer: a Lancet Oncology Commission","volume":"21","author":"Atun","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"2020082511345322100_B2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/1097-0142(196504)18:4<399::AID-CNCR2820180402>3.0.CO;2-G","article-title":"The African lymphoma: preliminary observations on response to therapy","volume":"18","author":"Burkitt","year":"1965","journal-title":"Cancer"},{"issue":"1","key":"2020082511345322100_B3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pcl.2014.09.010","article-title":"Pediatric lymphomas and histiocytic disorders of childhood","volume":"62","author":"Allen","year":"2015","journal-title":"Pediatr Clin North Am"},{"issue":"7335","key":"2020082511345322100_B4","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus particles in cultured lymphoblasts from Burkitt\u2019s lymphoma","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet"},{"issue":"24","key":"2020082511345322100_B5","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","article-title":"Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells","volume":"79","author":"Dalla-Favera","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4587","key":"2020082511345322100_B6","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1126\/science.6401867","article-title":"Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas","volume":"219","author":"Dalla-Favera","year":"1983","journal-title":"Science"},{"issue":"23","key":"2020082511345322100_B7","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt\u2019s lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2020082511345322100_B8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2141.2011.09008.x","article-title":"Burkitt lymphoma and the discovery of Epstein-Barr virus","volume":"156","author":"Epstein","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"2020082511345322100_B9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1365-2141.2008.07144.x","article-title":"Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin\u2019s lymphoma: results of the FAB\/LMB 96 international study","volume":"141","author":"Gerrard","year":"2008","journal-title":"Br J Haematol"},{"issue":"7","key":"2020082511345322100_B10","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2020082511345322100_B11","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2020082511345322100_B12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2010.245","article-title":"Non-Hodgkin\u2019s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols","volume":"25","author":"Burkhardt","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"2020082511345322100_B13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive Burkitt lymphoma\/leukaemia: a Children\u2019s Oncology Group Report","volume":"167","author":"Goldman","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"2020082511345322100_B14","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with stage III\/IV B-cell non-Hodgkin lymphoma: a Children\u2019s Oncology Group report","volume":"27","author":"Goldman","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2020082511345322100_B15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2010.33.3369","article-title":"Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (\u226515 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin\u2019s lymphoma: results of the FAB LMB 96 study","volume":"30","author":"Cairo","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"2020082511345322100_B16","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"key":"2020082511345322100_B17","first-page":"2333794X17715831","article-title":"Beyond endemic Burkitt lymphoma: navigating challenges of differentiating childhood lymphoma diagnoses amid limitations in pathology resources in Lilongwe, Malawi","volume":"4","author":"El-Mallawany","year":"2017","journal-title":"Glob Pediatr Health"},{"key":"2020082511345322100_B18","first-page":"339","article-title":"Agreement between diagnoses of childhood lymphoma assigned in Uganda and by an international reference laboratory","volume":"4","author":"Orem","year":"2012","journal-title":"Clin Epidemiol"},{"issue":"4","key":"2020082511345322100_B19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.5858\/2009-0443-EP.1","article-title":"Accuracy of Burkitt lymphoma diagnosis in constrained pathology settings: importance to epidemiology","volume":"135","author":"Ogwang","year":"2011","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"2020082511345322100_B20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood-2018-04-844472","article-title":"How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa","volume":"132","author":"Gopal","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2020082511345322100_B21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/jclinpath-2013-202099","article-title":"Remote and rapid pathological diagnosis in a resource challenged unit","volume":"67","author":"Carey","year":"2014","journal-title":"J Clin Pathol"},{"issue":"8","key":"2020082511345322100_B22","doi-asserted-by":"crossref","first-page":"e70361","DOI":"10.1371\/journal.pone.0070361","article-title":"Early experience after developing a pathology laboratory in Malawi, with emphasis on cancer diagnoses","volume":"8","author":"Gopal","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"2020082511345322100_B23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(13)70109-8","article-title":"Building a pathology laboratory in Malawi","volume":"14","author":"Gopal","year":"2013","journal-title":"Lancet Oncol"},{"key":"2020082511345322100_B24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/bloodadvances.2018GS112742","article-title":"Capacity building: a novel pediatric hematology-oncology fellowship program in sub-Saharan Africa","volume":"2","author":"Lubega","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"2020082511345322100_B25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ijc.2910260302","article-title":"Long-term experience with Burkitt\u2019s lymphoma in Uganda","volume":"26","author":"Olweny","year":"1980","journal-title":"Int J Cancer"},{"issue":"2","key":"2020082511345322100_B26","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/1097-0142(197008)26:2<474::AID-CNCR2820260232>3.0.CO;2-A","article-title":"Treatment of Burkitt\u2019s tumor with cyclophosphamide","volume":"26","author":"Ziegler","year":"1970","journal-title":"Cancer"},{"issue":"4","key":"2020082511345322100_B27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ijc.2910170404","article-title":"Treatment of Burkitt\u2019s lymphoma: randomized clinical trial of single-agent versus combination chemotherapy","volume":"17","author":"Olweny","year":"1976","journal-title":"Int J Cancer"},{"issue":"6","key":"2020082511345322100_B28","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/1097-0142(19800315)45:6<1507::AID-CNCR2820450634>3.0.CO;2-D","article-title":"Prognostic factors in Burkitt\u2019s lymphoma: importance of total tumor burden","volume":"45","author":"Magrath","year":"1980","journal-title":"Cancer"},{"issue":"3","key":"2020082511345322100_B29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0268-960X(92)90028-O","article-title":"Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies","volume":"6","author":"Hall","year":"1992","journal-title":"Blood Rev"},{"issue":"5 Pt 2","key":"2020082511345322100_B30","first-page":"146S","article-title":"An overview of cyclophosphamide and ifosfamide pharmacology","volume":"17","author":"Fleming","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"9","key":"2020082511345322100_B31","first-page":"3643","article-title":"The genetic origin of drug resistance in neoplasms: implications for systemic therapy","volume":"44","author":"Goldie","year":"1984","journal-title":"Cancer Res"},{"issue":"15","key":"2020082511345322100_B32","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1158\/1078-0432.CCR-12-3666","article-title":"Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients\u2019 blood cells: implications for cancer chemoimmunotherapy","volume":"19","author":"Moschella","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2020082511345322100_B33","first-page":"1155","article-title":"Evaluation of CCNU (NSC-79037) used for the prevention of CNS involvement in Burkitt\u2019s lymphoma","volume":"59","author":"Ziegler","year":"1975","journal-title":"Cancer Chemother Rep"},{"issue":"5773","key":"2020082511345322100_B34","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/bmj.3.5773.508","article-title":"Intrathecal chemotherapy in Burkitt\u2019s lymphoma","volume":"3","author":"Ziegler","year":"1971","journal-title":"BMJ"},{"issue":"3","key":"2020082511345322100_B35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841867709133941","article-title":"Cerebrospinal irradiation of Burkitt\u2019s lymphoma. Failure in preventing central nervous system relapse","volume":"16","author":"Olweny","year":"1977","journal-title":"Acta Radiol Ther Phys Biol"},{"issue":"2","key":"2020082511345322100_B36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ijc.2910100205","article-title":"Intensive chemotherapy in patients with generalized Burkitt\u2019s lymphoma","volume":"10","author":"Ziegler","year":"1972","journal-title":"Int J Cancer"},{"issue":"4","key":"2020082511345322100_B37","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/1097-0142(197710)40:4<1410::AID-CNCR2820400408>3.0.CO;2-M","article-title":"Combination chemotherapy in abdominal Burkitt\u2019s lymphoma","volume":"40","author":"Nkrumah","year":"1977","journal-title":"Cancer"},{"issue":"1","key":"2020082511345322100_B38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/mpo.10190","article-title":"Long term survival of children with Burkitt lymphoma in Malawi after cyclophosphamide monotherapy","volume":"40","author":"Kazembe","year":"2003","journal-title":"Med Pediatr Oncol"},{"issue":"3","key":"2020082511345322100_B39","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/pbc.24407","article-title":"Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting","volume":"60","author":"Hesseling","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2020082511345322100_B40","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(08)70139-6","article-title":"Treating Burkitt\u2019s lymphoma in Malawi, Cameroon, and Ghana","volume":"9","author":"Hesseling","year":"2008","journal-title":"Lancet Oncol"},{"issue":"1","key":"2020082511345322100_B41","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pbc.22746","article-title":"Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Pediatric Oncology Group (GFAOP)","volume":"56","author":"Traor\u00e9","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"2020082511345322100_B42","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.trstmh.2011.08.008","article-title":"Clinical characteristics, treatment and outcome of childhood Burkitt\u2019s lymphoma at the Uganda Cancer Institute","volume":"105","author":"Orem","year":"2011","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"6","key":"2020082511345322100_B43","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2141.2012.09236.x","article-title":"Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease","volume":"158","author":"Ngoma","year":"2012","journal-title":"Br J Haematol"},{"issue":"9","key":"2020082511345322100_B44","doi-asserted-by":"crossref","first-page":"e27813","DOI":"10.1002\/pbc.27813","article-title":"Survival of children with endemic Burkitt lymphoma in a prospective clinical care project in Uganda","volume":"66","author":"McGoldrick","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2020082511345322100_B45","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/pbc.25612","article-title":"Outcome is unchanged by adding vincristine upfront to the Malawi 28-day protocol for endemic Burkitt lymphoma","volume":"62","author":"Depani","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2020082511345322100_B46","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/bjh.13986","article-title":"Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi","volume":"173","author":"Stanley","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"2020082511345322100_B47","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/ijc.30170","article-title":"Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study","volume":"139","author":"Buckle","year":"2016","journal-title":"Int J Cancer"},{"issue":"2","key":"2020082511345322100_B48","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/1097-0142(197602)37:2<671::AID-CNCR2820370210>3.0.CO;2-D","article-title":"Burkitt\u2019s lymphoma: a clinical study of 110 patients","volume":"37","author":"Nkrumah","year":"1976","journal-title":"Cancer"},{"issue":"3","key":"2020082511345322100_B49","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/pbc.23050","article-title":"The use of ultrasound in endemic Burkitt lymphoma in Cameroon","volume":"58","author":"Marjerrison","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2020082511345322100_B50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08880018.2011.644881","article-title":"The Cameroon 2008 Burkitt lymphoma protocol: improved event-free survival with treatment adapted to disease stage and the response to induction therapy","volume":"29","author":"Hesseling","year":"2012","journal-title":"Pediatr Hematol Oncol"},{"key":"2020082511345322100_B51","first-page":"1","article-title":"Advanced Burkitt lymphoma in sub-Saharan Africa pediatric units: results of the Third Prospective Multicenter Study of the Groupe Franco-Africain d\u2019Oncologie P\u00e9diatrique","volume":"5","author":"Bouda","year":"2019","journal-title":"J Glob Oncol"},{"issue":"10","key":"2020082511345322100_B52","doi-asserted-by":"crossref","first-page":"e27275","DOI":"10.1002\/pbc.27275","article-title":"The changing clinical pattern of endemic Burkitt lymphoma in Western Africa: experience from a tertiary center in Ghana","volume":"65","author":"Offor","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"8149","key":"2020082511345322100_B53","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(79)92627-8","article-title":"Cure of Burkitt\u2019s lymphoma. Ten-year follow-up of 157 Ugandan patients","volume":"2","author":"Ziegler","year":"1979","journal-title":"Lancet"},{"issue":"6","key":"2020082511345322100_B54","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/bjh.14440","article-title":"The use of anthracyclines in the treatment of endemic Burkitt lymphoma","volume":"177","author":"Molyneux","year":"2017","journal-title":"Br J Haematol"},{"issue":"6","key":"2020082511345322100_B55","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjh.14716","article-title":"Dissecting heterogeneous outcomes for paediatric Burkitt lymphoma in Malawi after anthracycline-based treatment","volume":"181","author":"Westmoreland","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"2020082511345322100_B56","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1097-0142(19800215)45:4<630::AID-CNCR2820450403>3.0.CO;2-5","article-title":"A randomized trial of combined modality therapy of childhood non-Hodgkin\u2019s lymphoma","volume":"45","author":"Murphy","year":"1980","journal-title":"Cancer"},{"key":"2020082511345322100_B57","doi-asserted-by":"crossref","first-page":"130680","DOI":"10.1155\/2012\/130680","article-title":"Towards curative therapy in burkitt lymphoma: the role of early African studies in demonstrating the value of combination therapy and CNS prophylaxis","volume":"2012","author":"Magrath","year":"2012","journal-title":"Adv Hematol"},{"issue":"2","key":"2020082511345322100_B58","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.1989.7.2.186","article-title":"Non-Hodgkin\u2019s lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution","volume":"7","author":"Murphy","year":"1989","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020082511345322100_B59","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1046\/j.1365-2141.2003.04134.x","article-title":"Burkitt\u2019s and Burkitt-like lymphoma in children and adolescents: a review of the Children\u2019s Cancer Group experience","volume":"120","author":"Cairo","year":"2003","journal-title":"Br J Haematol"},{"issue":"5","key":"2020082511345322100_B60","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/mpo.1226","article-title":"Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: a report from the Children\u2019s Cancer Group","volume":"37","author":"Sposto","year":"2001","journal-title":"Med Pediatr Oncol"},{"issue":"2","key":"2020082511345322100_B61","first-page":"113","article-title":"Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma","volume":"13","author":"El-Mallawany","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10","key":"2020082511345322100_B62","first-page":"3294","article-title":"Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-M\u00fcnster Group Trial NHL-BFM 90","volume":"94","author":"Reiter","year":"1999","journal-title":"Blood"},{"issue":"3","key":"2020082511345322100_B63","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-03-0973","article-title":"The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95","volume":"105","author":"Woessmann","year":"2005","journal-title":"Blood"},{"issue":"19","key":"2020082511345322100_B64","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.2009.26.6791","article-title":"Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin\u2019s lymphoma and Burkitt leukemia","volume":"28","author":"Meinhardt","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020082511345322100_B65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JCO.1991.9.1.123","article-title":"High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children","volume":"9","author":"Patte","year":"1991","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020082511345322100_B66","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"issue":"12","key":"2020082511345322100_B67","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.1986.4.12.1732","article-title":"Results of treatment of advanced-stage Burkitt\u2019s lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine","volume":"4","author":"Murphy","year":"1986","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020082511345322100_B68","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/pbc.24416","article-title":"Children\u2019s Oncology Group\u2019s 2013 blueprint for research: non-Hodgkin lymphoma","volume":"60","author":"Bollard","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"27","key":"2020082511345322100_B69","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2014.59.5827","article-title":"Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead","volume":"33","author":"Minard-Colin","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020082511345322100_B70","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2141.2008.06988.x","article-title":"Recent advances in the understanding and management of diffuse large B-cell lymphoma in children","volume":"142","author":"Reiter","year":"2008","journal-title":"Br J Haematol"},{"issue":"6","key":"2020082511345322100_B71","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1365-2141.2011.09024.x","article-title":"Risk factors and treatment of childhood and adolescent Burkitt lymphoma\/leukaemia","volume":"156","author":"Miles","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"2020082511345322100_B72","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.1995.13.2.359","article-title":"Non-Hodgkin\u2019s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage\u2013a report of the Berlin-Frankfurt-M\u00fcnster Group","volume":"13","author":"Reiter","year":"1995","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020082511345322100_B73","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjh.15734","article-title":"Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies","volume":"185","author":"Egan","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"2020082511345322100_B74","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1309\/AJCPHY69XVJGULKO","article-title":"Independent diagnostic accuracy of flow cytometry obtained from fine-needle aspirates: a 10-year experience with 451 cases","volume":"135","author":"Savage","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"2020082511345322100_B75","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.transci.2007.06.001","article-title":"Fine needle aspiration biopsy and flow cytometry in the diagnosis of lymphoma","volume":"37","author":"Swart","year":"2007","journal-title":"Transfus Apheresis Sci"},{"key":"2020082511345322100_B76","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1002\/cyto.b.20400","article-title":"Flow cytometry as the spearhead for delivering sustainable and versatile laboratory services to HIV-burdened health care systems of the developing world: a Caribbean model","volume":"74","author":"Abayomi","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"key":"2020082511345322100_B77","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1097\/QAI.0b013e3181bbc9f5","article-title":"Developing laboratory systems and infrastructure for HIV scale-up: A tool for health systems strengthening in resource-limited settings","volume":"52","author":"Justman","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"2020082511345322100_B78","first-page":"32","article-title":"Benchtop flow cytometry helps monitor HIV in sub-Saharan Africa","volume":"44","author":"Mulry","year":"2012","journal-title":"MLO Med Lab Obs"},{"key":"2020082511345322100_B79","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2018GS112620","article-title":"Improving diagnosis and treatment of acute childhood leukemia in Uganda: impact of flow cytometry","volume":"2","author":"Namazzi","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"2020082511345322100_B80","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/pbc.20254","article-title":"The 2000 Burkitt Lymphoma Trial in Malawi","volume":"44","author":"Hesseling","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2020082511345322100_B81","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/pbc.21452","article-title":"Treatment of B-cell lymphoma with LMB modified protocols in Africa\u2013report of the French-African Pediatric Oncology Group (GFAOP)","volume":"50","author":"Harif","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2020082511345322100_B82","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/00043426-200407000-00014","article-title":"Treatment of children with B-cell non-Hodgkin\u2019s lymphoma in developing countries: the experience of a single center in Brazil","volume":"26","author":"Klumb","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"2020082511345322100_B83","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/mpo.10288","article-title":"Treatment of B-cell malignancies in children with a modified BFM-NHL 90 protocol in Argentina","volume":"41","author":"Chantada","year":"2003","journal-title":"Med Pediatr Oncol"},{"issue":"1","key":"2020082511345322100_B84","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/pbc.21046","article-title":"Treatment of pediatric non-Hodgkin lymphomas in a country with limited resources: results of the first national protocol in Nicaragua","volume":"50","author":"Baez","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2020082511345322100_B85","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/pbc.20116","article-title":"Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol","volume":"43","author":"Acquatella","year":"2004","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2020082511345322100_B86","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-9378-9-19","article-title":"Burkitt lymphoma: epidemiological features and survival in a South African centre","volume":"9","author":"Stefan","year":"2014","journal-title":"Infect Agent Cancer"},{"issue":"5","key":"2020082511345322100_B87","doi-asserted-by":"crossref","first-page":"e27621","DOI":"10.1002\/pbc.27621","article-title":"Outcome of pediatric non-Hodgkin lymphoma in Central America: a report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA)","volume":"66","author":"Pe\u00f1a-Hernandez","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2020082511345322100_B88","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pbc.21753","article-title":"A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent\/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"52","author":"Griffin","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2020082511345322100_B89","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/bloodadvances.2018029199","article-title":"Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi","volume":"3","author":"Painschab","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"2020082511345322100_B90","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bjh.15944","article-title":"Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M","volume":"186","author":"Maschan","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"2020082511345322100_B91","doi-asserted-by":"crossref","first-page":"e20170525","DOI":"10.1542\/peds.2017-0525","article-title":"Lessons from pediatric HIV: a case for curative intent in pediatric cancer in LMICs","volume":"140","author":"Miller","year":"2017","journal-title":"Pediatrics"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/16\/4007\/1756272\/advancesadv2020002178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/16\/4007\/1756272\/advancesadv2020002178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T17:46:24Z","timestamp":1668015984000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/16\/4007\/463452\/Five-decades-of-low-intensity-and-low-survival"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,25]]},"references-count":91,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002178","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,25]]}}}